Table 4 Mainly directed targets of interventional clinical trials of drugs
From: Analyzing MASLD interventional clinical trial registration based on the ClinicalTrials.gov database
Categorization | Targets | Drug name | Number |
|---|---|---|---|
Inflammatory and immunomodulatory targets | ASBT | Volixibat (SHP626) | 2 |
Caspase | Emricasan (IDN-6556) | 2 | |
Gal-3 | GR-MD-02 | 2 | |
LTA4H | LYS006 | 1 | |
RARs | Fenretinide | 1 | |
RORγt | BMS-986,251 | 1 | |
SSAO | BI 1,467,335, TERN-201 | 2 | |
TLR-4 | JKB-121 | 1 | |
CCR | Cenicriviroc, Leronlimab | 6 | |
AT1R | Losartan potassium | 2 | |
Metabolic and energy balance related targets | ACC | Firsocostat, PF-05221304, MK-4074 | 8 |
AMPK | PXL770, Glucophage (Metformin) | 4 | |
ANT | HU6 | 1 | |
DGAT | Pradigastat (LCQ908), PF-06865571 | 2 | |
FGF21 | BMS-986,036, Efruxifermin (EFX), Pegozafermin | 6 | |
GLP-1 | Efinopegdutide, Exenatide, Semaglutide | 8 | |
GSS | Cysteamine | 1 | |
HPK1 | AZ compound | 1 | |
IGF-1 | Growth hormone, Somatropin | 2 | |
LEPR | Metreleptin | 4 | |
Lipid metabolism-related targets | ANGPTL3 | ISIS 703,802 | 1 |
AR | LPCN 1144 | 2 | |
FABP6 | Colesevelam Hcl | 1 | |
LIPA | Sebelipase Alfa | 2 | |
NPC1L1 | Ezetimibe | 1 | |
PPAR | Elafibranor (GFT505), Lanifibranor (IVA337), pioglitazone, PXL065, Seladelpar, Fenofibrate, MSDC-0602Â K | 18 | |
SCD1 | Aramchol | 2 | |
SGLT | Licogliflozin, Dapagliflozin | 3 | |
| Â | Beta Glucosylceramide | 1 | |
Signal transduction-related targets | ASK1 | Selonsertib (SEL) | 5 |
GRF | Tesamorelin | 1 | |
JNK | CC-90,001, GWP42003 | 2 | |
PDE | Roflumilast, Pentoxifylline (PTX) | 3 | |
Enzyme targets | Bacterial RNA polymerase inhibitors | Rifaximin | 1 |
COX | Aspirin | 1 | |
DPP4 | Sitagliptin | 2 | |
HMG-CoA reductase inhibitors | Atorvastatin, pitavastatin | 2 | |
LOXL2 | Simtuzumab (SIM) | 1 | |
Transglutaminases inhibitors | DR cysteamine bitartrate capsule | 1 | |
Bile acid metabolic targets | FXR | Cilofexor (GS-9674), EDP-305, Nidufexor (LMB763), Obeticholic acid (INT-747), TERN-101, Tropifexor (LJN452), Vonafexor, HTD1801 | 20 |
IBAT | Elobixibat | 1 | |
Glucose metabolic targets | Â | ORMD-0801, insulin | 3 |
Regulates intestinal flora targets | Â | Align Probiotic Supplement Capsule | 1 |
Multiple targets | 5-LOX, LTRs | MN-001 | 1 |
CCR2/5, PPAR | Gemcabene | 2 | |
GLP-1, GCGR | MEDI0382 | 1 | |
Hepatitis B virus structural protein, CYPA | CRV431 | 1 | |
IKKε, TBK1 | Amlexanox | 2 | |
KLB, FGFR1 | BFKB8488A, MK-3655 | 2 | |
MR, GR | Miricorilant | 1 | |
NPC1L1, FXR | EZ-Urso combination therapy | 1 | |
PRKAB1, PDE5A | Leu-Met-Sil | 1 | |
Other | Vitamin B | Niacin | 1 |
Vitamin E | 4 | 4 | |
Proton pump inhibitor | Rabeprazol sodium | 1 | |
thrombin | Dabigatran Etexilate, Eltrombopag | 2 | |
Unsaturated fatty acid | EPA-E, Opti-EPA, Epeleuton, Vascepa, Fish Oil Supplementation, OMACOR, Omega-3 carboxylic acids | 9 | |
| Â | KRG (Korea Red ginseng) | 1 | |
| Â | IdB 1016 (Siliphos), Silymarin | 2 | |
| Â | SAMe | 1 |